Weight-adjusted adenosine and first-dose conversion success in supraventricular tachycardia: a prospective cohort study
Irish Journal of Medical Science (1971 -) · 2026-10 · 195 (5) · 2735-2743
DOI: 10.1007/s11845-026-04530-9 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Irish Journal of Medical Science (1971 -), online erschienen am 04.07.2026. Verfasst von Merve Osoydan Satici und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Universty of Health Sciences Umraniye Research and Training Hospital, Elmalikent Mahallesi, Adem Yavuz Caddesi, No:…. Hauptthemen laut MEDLINE: Adenosine, Anti-Arrhythmia Agents, Body Weight, Tachycardia, Supraventricular. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Current guidelines recommend a standard fixed initial dose of 6 mg adenosine for supraventricular tachycardia (SVT). However, rising obesity rates may reduce the efficacy of this fixed-dose strategy. We aimed to evaluate the impact of body weight on first-dose adenosine success and to identify an optimal weight-adjusted dose. METHODS: This prospective observational study included 155 adult SVT patients refractory to vagal maneuvers at a tertiary emergency department (ED). All patients received an initial 6 mg dose of IV adenosine. Success was defined as conversion to sinus rhythm (SR). Weight-adjusted doses (mg/kg) were compared between success and failure groups, and ROC analysis was performed to identify optimal cutoffs. RESULTS: The first-dose conversion rate was 58.1%. Patients with successful conversion had significantly lower body weight (74.0 ± 14.3 kg vs. 81.9 ± 16.2 kg, p = 0.001). The weight-adjusted dose was significantly higher in the success group compared to the failure group (0.082 vs. 0.074 mg/kg, p < 0.001). ROC analysis revealed that a weight-adjusted dose ≥ 0.076 mg/kg predicted conversion with 67.8% sensitivity and 60.0% specificity. Specificity increased to 90.8% at a cutoff of ≥ 0.10 mg/kg. CONCLUSION: Our findings suggest that the standard fixed 6 mg initial dose of adenosine may be insufficient for contemporary populations with higher body weight. A weight-adjusted initial dose, particularly targeting 0.09-0.1 mg/kg, may optimize first-dose conversion to sinus rhythm in patients with SVT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, Universty of Health Sciences Umraniye Research and Training Hospital, Elmalikent Mahallesi, Adem Yavuz Caddesi, No:1 Umraniye, Istanbul, Turkey. merveosoydan@gmail.com.
- Department of Emergency Medicine, Universty of Health Sciences Umraniye Research and Training Hospital, Elmalikent Mahallesi, Adem Yavuz Caddesi, No:1 Umraniye, Istanbul, Turkey.
Zitieren
APA
Satici, M. O., Aksel, G., İslam, M. M., Erdil Gündüz, F. N., Tarakçıoğlu, D., Eker, N., Küka, B., Gündüz, A. R., Güneş, A., Anıl, M. A., Altın, C., & Eroğlu, S. E. (2026). Weight-adjusted adenosine and first-dose conversion success in supraventricular tachycardia: a prospective cohort study. Irish Journal of Medical Science (1971 -), 195(5), 2735-2743. https://doi.org/10.1007/s11845-026-04530-9
Vancouver
Satici MO, Aksel G, İslam MM, Erdil Gündüz FN, Tarakçıoğlu D, Eker N, et al. Weight-adjusted adenosine and first-dose conversion success in supraventricular tachycardia: a prospective cohort study. Irish Journal of Medical Science (1971 -). 2026;195(5):2735-2743. doi:10.1007/s11845-026-04530-9
BibTeX
@article{Satici2026,
author = {Satici, Merve Osoydan and Aksel, Gökhan and İslam, Mehmet Muzaffer and Erdil Gündüz, Fahriye Naz and Tarakçıoğlu, Dilşa and Eker, Nevin and Küka, Burak and Gündüz, Alper Reşit and Güneş, Ahmed and Anıl, Muhammed Arda and Altın, Ceyda and Eroğlu, Serkan Emre},
title = {Weight-adjusted adenosine and first-dose conversion success in supraventricular tachycardia: a prospective cohort study},
journal = {Irish Journal of Medical Science (1971 -)},
year = {2026},
volume = {195},
number = {5},
pages = {2735--2743},
doi = {10.1007/s11845-026-04530-9}
}
EUVIMED